Relapsed/Refractory Patients:

Treatment Options - Aplidin


Aplidin® (plitidepsin)


What is Aplidin?

Aplidin (plitidepsin) is an anti-tumor agent being developed by PharmaMar that was originally isolated from a marine organism known as a sea squirt. Aplidin is given as an intravenous infusion every 2 weeks.

What do we know about Aplidin’s activity in myeloma?

Laboratory studies have shown that Aplidin has potent anti-myeloma activity against patient myeloma cells, including those that are resistant to other myeloma agents. It also shows additive or synergistic effects with other anti-myeloma drugs.

Final results of a small Phase II study in patients with relapsed/refractory myeloma (n=47) show activity of Aplidin in a heavily-pretreated patient population. The overall response rate (complete, partial, and minimal responses) was 13% with Aplidin alone. When dexamethasone was added (n=18), the overall response rate increased to 22%. Aplidin was well tolerated. Anemia and low platelet counts were the most frequent severe hematologic toxicities, and transient increases in liver enzymes and fatigue were the most common nonhematologic side effects.

How is Aplidin currently being studied in myeloma?

Aplidin is currently being evaluated in combination with dexamethasone in a Phase III trial in relapsed/refractory myeloma that is being conducted in the United States, Europe, and Australia. A total of 250 patients will be enrolled in the study, called ADMYRE, and the combination will be compared to dexamethasone alone.


To find a clinical trial, call 1-866-603-MMCT (-6628) or click here to go to the MMRF Patient Navigator Program.